Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.
Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.
According to Jinse Finance APP, Federal Reserve Governor Christopher Waller said on Thursday that if economic data continues to evolve as expected, he anticipates further rate hikes to help inflation return more promptly to the Fed’s 2% target.
Waller stated in a speech at the Istanbul Economic Forum that there is some flexibility regarding the timing of rate hikes. “Rate hikes don't have to occur at consecutive meetings, but they should be implemented within an acceptable timeframe.”
The Federal Open Market Committee (FOMC) raised the federal funds rate by 25 basis points to a range of 3.75% to 4% in September, after the rate had remained unchanged for nine consecutive months.
Inflation Remains Above the Fed’s Target
Waller noted that August data showed the core Personal Consumption Expenditures (PCE) price index rose 0.25% month-on-month, with a 3% year-on-year increase over 12 months. “This is clearly above our target and does not show sufficient progress,” he said.
Waller stated that the labor market remains stable while “inflation is excessively high,” adding, “At least in the near term, policy will focus on the inflation side of our mandate.”
Waller said his decision to shift policy stance in September was not based on one month’s inflation data, but reflected the “overall trend of evidence over several months,” including a strengthening labor market and a range of persistent inflationary forces.
The Fed Governor said that stronger economic activity in the second half of the year made him less concerned about monetary tightening causing a damaging slowdown. He also noted concern that a recent acceleration in inflation may lead consumers, investors, and pricing businesses to raise expectations for future inflation.
Highlighting Energy, AI, and Tariffs
Waller said hopes for a swift end to conflict in the Middle East have been dashed, and experts warn that low inventories and damaged infrastructure could keep oil prices elevated through 2027.
The Fed Governor pointed out that there is increasing evidence that “the AI construction boom is significantly driving up prices for high-tech consumer goods,” while ongoing trade disputes may result in new tariffs, once again placing upward pressure on inflation.
Waller said these forces “are overwhelming the fleeting signs of progress toward the 2% inflation target.”
Waller emphasized that the Summary of Economic Projections (SEP) can signal possible directions for monetary policy, but also stressed that “the path of monetary policy is not pre-set” and will depend on subsequent data and its implications for the Fed’s dual mandate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Market Movements | Oil stocks generally rise, BP (BP.US) up over 3%
On Thursday, oil stocks generally rose, with BP (BP.US) up more than 3%.
CleanTech Lithium expands foothold in Argentina
BUZZ-Better Home & Finance shares rise after announcing a $30 million stock buyback plan
October 8 - Better Home & Finance (BETR.O), a mortgage and home equity financing company, saw its stock price rise 3.8% to $10.30 in pre-market trading after announcing a share repurchase plan. BETR stated that its board of directors has approved a stock buyback program of up to $30 million, with an initial phase of $10 million to kick off the repurchase. The company plans to adjust the pace of the repurchase based on realized operational cost savings and asset disposal progress, such as the proposed sale of its UK bank subsidiary. The buyback program is set to expire on October 8, 2027. In August, BETR forecasted that its Q3 revenue would be below Wall Street expectations as it focuses on partnership opportunities and accelerating the development of its home equity credit business. As of the previous trading day's close, the company's market capitalization was approximately $175 million. As of Wednesday, the stock has dropped about 70% year-to-date. According to LSEG data, seven out of eight analysts rate the stock as "strong buy" or "buy," with one rating it as "hold"; the median target price is $25. (For the convenience of non-English speakers, Reuters provides translated automated reports in several other languages. As automated translations may contain errors or lack required context, Reuters does not guarantee the accuracy of these texts and provides them simply for convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Crypto prices
More
